HOXA1 silencing inhibits cisplatin resistance of oral squamous cell carcinoma cells via IκB/NF-κB signaling pathway

• Published in: Anti-cancer drugs Vol. 35; no. 6; p. 492
• Main Authors: Zhu, Ruifeng, Mao, Yiting, Xu, Xianzhi, Li, Yingying, Zheng, Jiwei
• Format: Journal Article
• Language: English
• Published: England 01.07.2024
• Subjects: Antineoplastic Agents - pharmacology; Apoptosis - drug effects; Carcinoma, Squamous Cell - drug therapy; Carcinoma, Squamous Cell - genetics; Carcinoma, Squamous Cell - metabolism; Carcinoma, Squamous Cell - pathology; Cell Line, Tumor; Cell Proliferation - drug effects; Cell Survival - drug effects; Cisplatin - pharmacology; Drug Resistance, Neoplasm; Homeodomain Proteins - genetics; Homeodomain Proteins - metabolism; Humans; I-kappa B Proteins - metabolism; Mouth Neoplasms - drug therapy; Mouth Neoplasms - genetics; Mouth Neoplasms - pathology; NF-kappa B - metabolism; NF-KappaB Inhibitor alpha - metabolism; Signal Transduction - drug effects; Squamous Cell Carcinoma of Head and Neck - drug therapy; Squamous Cell Carcinoma of Head and Neck - genetics; Squamous Cell Carcinoma of Head and Neck - metabolism; Squamous Cell Carcinoma of Head and Neck - pathology; Transcription Factors - genetics; Transcription Factors - metabolism

The resistance of oral squamous cell carcinoma (OSCC) cells to cisplatin remains a tough nut to crack in OSCC therapy. Homeobox A1 (HOXA1) overexpression has been detected in head and neck squamous carcinoma (HNSC). Accordingly, this study aims to explore the potential role and mechanism of HOXA1 on...